|
TMED7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.83389999994532E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.31680000000778E-05 |
| Normal-vs-Stage2 |
1.070360E-01 |
| Normal-vs-Stage3 |
6.66960000006434E-07 |
| Normal-vs-Stage4 |
1.61300000023346E-08 |
| Stage1-vs-Stage2 |
1.181400E-01 |
| Stage1-vs-Stage3 |
4.955800E-02 |
| Stage1-vs-Stage4 |
2.479500E-03 |
| Stage2-vs-Stage3 |
8.577000E-03 |
| Stage2-vs-Stage4 |
7.021500E-04 |
| Stage3-vs-Stage4 |
1.522240E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.89720000043359E-07 |
| Normal-vs-AfricanAmerican |
2.561900E-02 |
| Normal-vs-Asian |
4.6404000000333E-06 |
| Caucasian-vs-AfricanAmerican |
4.259400E-01 |
| Caucasian-vs-Asian |
5.187200E-01 |
| AfricanAmerican-vs-Asian |
3.602400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.50683999999845E-05 |
| Normal-vs-Female |
3.85430000000575E-05 |
| Male-vs-Female |
3.357800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.759900E-04 |
| Normal-vs-Age(41-60Yrs) |
3.44649999994839E-06 |
| Normal-vs-Age(61-80Yrs) |
6.0952000000003E-05 |
| Normal-vs-Age(81-100Yrs) |
1.636210E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.161800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.234400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.092800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.028000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.283600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.895600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.544200E-03 |
| Classical-VS-Follicular |
3.344900E-03 |
| Classical-VS-Other |
4.728800E-01 |
| Classical-VS-Normal |
2.45379999996853E-06 |
| Tall-VS-Follicular |
1.65629999999695E-05 |
| Tall-VS-Other |
6.358400E-01 |
| Tall-VS-Normal |
4.02390000209252E-08 |
| Follicular-VS-Other |
1.249570E-01 |
| Follicular-VS-Normal |
1.570450E-01 |
| Other-VS-Normal |
1.303900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.264780E-03 |
| Normal-vs-N1 |
5.37809999867633E-08 |
| N0-vs-N1 |
2.939100E-03 |
|
|
